

5. Literaturverzeichnis

5. Literaturverzeichnis

1. Ahlstrom H, Malmstrom PU, Letocha H, Andersson J, Langstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. *Acta Radiol* 1996;37: 180-185.
2. Alger JR, Frank JA, Fulham MJ, DeSouza BX, Duhaney MO, Inscoe SW, Black JL, van Zijl PC, Moonen CT et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. *Radiology* 1990;177: 617-618.
3. Al-Mefty O, Kersh JE, Routh A, Smith RR. The long-term side effects of radiation therapy for benign brain tumors in adults. *J Neurosurg* 1990;73: 502-512.
4. Amthauer H, Wurm R, Kuczer D, Ruf J, Michel R, Eisenacher J, Stockhammer F, Denecke T, Felix R, Plotkin M. Relevance of image fusion with MRI for the interpretation of ¹²³I-IMT scans in patients with suspected recurrent or residual brain tumors. *Clin Nucl Med* 2006; 31: 189-192.
5. Ancrì D, Basset JY, Lonchamp MF, Etavard C. Diagnosis of cerebral lesions by Thallium 201. *Radiology* 1978; 128: 417-422.
6. Atlas SW (ed.) *Magnetic resonance imaging of the brain and spine*. 2nd ed. Lippincott - Raven, New York. (1996).
7. Bader JB, Samnick S, Moringlane JR, Feiden W, Schaefer A, Kremp S, Kirsch CM. Evaluation of I-3-[¹²³I]iodo- α -methyltyrosine SPET and [¹⁸F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. *Eur J Nucl Med* 1999;26: 144-151.
8. Baillet G, Albuquerque L, Chen Q, Poisson M, Delattre JY. Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi. *Eur J Nucl Med* 1994;21: 1061-1066.
9. Barker FG 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant gliomas. *Cancer* 1997;79: 115-126.
10. Barker FG, Chang SM, Huhn SL, Davis RL, Gutin PH, McDermott MW, Wilson CB, Prados MD: Age and the risk of anaplasia in magnetic resonance-enhancing supratentorial cerebral tumors. *Cancer* 1997; 80:936-941.
11. Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. *Semin Nucl Med* 2003;33: 148-162.
12. Bergström M, Collins VP, Ehrin E, Ericson K, Ericson L, Greitz T, Halldin C, von Holst H, Langstrom B, Lilja A. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [⁶⁸Ga]EDTA, [¹¹C]glucose, and [¹¹C]methionine. *J Comput Assist Tomogr* 1983;7: 1062-1066.
13. Biersack HJ, Coenen HH, Stocklin G, Reichmann K, Bockisch A, Oehr P, Kashab M, Rollmann O. Imaging of brain tumors with L-3-[¹²³I]iodo- α -methyl tyrosine and SPECT. *J Nucl Med* 1989;30: 110-112.
14. Blandino G, Bonanno N, Gonforti P, Meduri M. In ^{113m}DTPA brain scanning in the diagnosis of space occupying lesions. *Acta Isot (Padova)* 1969;10: 91-102.
15. Blasberg R. Prediction of brain tumor therapy response by PET. *J Neurooncol* 1994;22: 281-286.

5. Literaturverzeichnis

16. Boring CC, Squires TS, Tong TS. Cancer statistics,1992. *CA Cancer J Clin* 1992;42: 19-38.
17. Brock M, Cevos-Navarro J, Holdorff B. Changes in intracranial pressure associated with delayed cerebral radionecrosis. *Surg Neurol* 1984;22: 8-16.
18. Bronstein AD, Nyberg DA, Schrarzt AN, Shuman WP, Griffin BR. Soft-tissue changes after head and neck radiation: CT findings. *Am J Neuroradiol* 1989;10: 71-175.
19. Brucher JM. Neuropathological diagnosis with stereotactic biopsies. Possibilities, difficulties and requirements. *Acta Neurochir (Wien)* 1993;124: 37-39.
20. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hanicke W, Sauter R, Hamburger C. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. *Radiology* 1989;172: 541-548.
21. Byrne TN. Imaging of gliomas. *Semin Oncol* 1994;21: 162-71.
22. Chamberlain M, Murovic J, Levin V. Absence of contrast enhancement on CT brain scans of patients with malignant gliomas. *Neurology* 1998; 38: 1371-1374.
23. Chang L. A method for attenuation correction in computed tomography. *IEEE Trans Nucl Sci* 1978;25: 638-643.
24. Chang YW, Yoon HK, Shin HJ, Roh HG, Cho JM. MR imaging of glioblastoma in children: usefulness of diffusion/perfusion-weighted MRI and MR spectroscopy. *Pediatr Radiol* 2003;33: 836-842.
25. Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers ML. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. *J Neurooncol* 2004;69: 101-117.
26. Choi JY, Kim SE, Shin HJ, Kim BT, Kim JH. Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose. *J Neurooncol* 2000;46: 63-70.
27. Davis JP, Maisey NM, Chevreton EB. Positron emission tomography: a useful imaging technique for otolaryngology, head and neck surgery? *J Laryngol Otol* 1998;112: 125-127.
28. De Salles AA, Brekhus SD, De Souza EC, Behnke EJ, Farahani K, Anzai Y, Lufkin R. Early postoperative appearance of radiofrequency lesions on magnetic resonance imaging. *Neurosurgery* 1995;36: 932-936.
29. De Witte O, Hilderbrand J, Luxen A, Goldman S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. *Cancer* 1994;74: 2836-2842.
30. De Witte O, Lefranc F, Levivier M, Salmon I, Brotchi J, Goldman S: FDG-PET as a prognostic factor in high-grade astrocytoma. *J Neurooncol* 2000;49: 157-163.
31. De Witte O, Levivier M, Violon P, Salmon I, Damhaut P, Wikler D, Hildebrand J, Brotchi J, Goldman S. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. *Neurosurgery* 1996;39: 470-476.
32. Dean BL, Drayer BP, Bird CR, Flom RA, Hodak JA, Coons SW, Carey RG. Gliomas: classification with MR imaging. *Radiology* 1990;174: 411-415.
33. Delbeke D, Meyerowitz C, Lapidus RL. Optimal cutoff levels of [18F] fluorodeoxyglucose in the differentiation of low-grade from high-grade brain tumors with PET. *Radiology* 1995;195: 47-52.

5. Literaturverzeichnis

34. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kuffa CV, Kessler RM, Johnston GS, Manning RG, Wolf AP. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. *Neurology* 1982;32: 1323-1329.
35. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kuffa CV. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. *AJR Am J Roentgenol* 1988;150: 189-197.
36. Dierckx RA, Martin JJ, Dobbeleir A, Crols R, Neetens I, De Deyn PP. Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumours. *Eur J Nucl Med* 1994;21: 621-633.
37. Dierickx LO, Everaert H, Deron P, Voordeckers M, Lahoutte T, Bossuyt A. Evaluation of the response to therapy of head and neck squamous cell carcinoma by using 3-[123I]iodo-L-alpha-methyl tyrosine and single photon emission tomography. *Nucl Med Commun* 2003;24: 633-641.
38. Dierickx LO, Lahoutte T, Deron P, Caveliers V, Vanhove C, Everaert H, Bossuyt A. Diagnosis of recurrent head and neck squamous cell carcinoma with 3-[123I]iodo-L-alpha-methyltyrosine SPET. *Eur J Nucl Med* 2001;28: 282-287.
39. Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH. Brain radiation lesions: MR imaging. *Radiology* 1986;158: 149-155.
40. Dowling Ch, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day MR, Henry RG, Dillon WP, Nelson SJ, Vigneron DB. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. *Am J Neuroradiol* 2001;22: 604-612.
41. Dunne AA, Budach VG, Wagner W, Werner JA. Management of N0 neck in head and neck cancer: current controversies. *Onkologie* 2004;27: 363-367.
42. Eastwood JD, Provenzale JM. Cerebral blood flow, blood volume, and vascular permeability of cerebral glioma assessed with dynamic CT perfusion imaging. *Neuroradiology* 2003;45: 373-376.
43. Ericson K, Lilja A, Bergstrom M, Collins VP, Eriksson L, Ehrin E, von Holst H, Lundqvist H, Langsrom B B, Mosskin M. Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. *J Comput Assist Tomogr* 1985;9: 683-689.
44. Farber LA, Benard F, Machtay M, Smith RJ, Weber RS, Weinstein GS, Chalian AA, Alavi A, Rosenthal DI. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography. *Laryngoscope* 1999;109: 970-975.
45. Fayed N, Modrego PJ. The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. *J Neurooncol.* 2005;72 :261-265.
46. Field AS, Alexander AL. Diffusion tensor imaging in cerebral tumor diagnosis and therapy. *Top Magn Reson Imaging* 2004;15: 315-324.
47. Fischbein NJ, Assar OS, Caputo GR, Kaplan MJ, Singer MI, Price DC, Dillon WP, Hawkins RA. Clinical utility of positron emission tomography with 18F-

5. Literaturverzeichnis

- fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. *Am J Neuroradiol* 1998;19: 1189-1196.
48. Flamen P, Bernheim N, Deron P, Caveliers V, Chavatte K, Franken PR, Bossuyt A. Iodine-123 alpha-methyl-I-tyrosine single-photon emission tomography for the visualization of head and neck squamous cell carcinomas. *Eur J Nucl Med* 1998;25: 177-181.
 49. Floeth F, Pauleit D, Wittsack HJ, Langen KJ, Reifenberger G, Hamaher K, Messing-Junger M, Zilles K, Weber F, Stummer W, Stiegler HJ, Woebker G, Muller HW, Coenen HH, Sabel M. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. *J Neurosurg* 2005;102: 318-327.
 50. Frahm J, Bruhn H, Hanicke W, Merboldt KD, Mursch K, Markakis E. Localized proton NMR spectroscopy of brain tumors using short-echo time STEAM sequences. *J Comput Assist Tomogr* 1991;15: 915-922.
 51. Francavilla TL, Miletich RS, Di Chiro G, Patronas NJ, Rizzoli HV, Wright DC. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. *Neurosurgery* 1989;24: 1-5.
 52. Friedman HS, Kerby T, Calvert H. Temozolamid and treatment of malignant gliomas. *Clin Cancer Res* 2000;6: 2585-2597.
 53. Fuhlam MJ, Bizzi A, Dietz MJ, Shish HH, Raman R, Sobering Gs, Frank JA, Dwyer AJ, Alger JR, Di Chiro G. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. *Radiology* 1992;185: 675-686.
 54. Fukuyama H, Kameyama M, Harada K, Fujimoto N, Kobayashi A, Taki W, Ishikawa T, Handa H, Tanada S, Torizuka K. Thalamic tumours invading the brain stem produce crossed cerebellar diaschisis demonstrated by PET. *J Neurol Neurosurg Psychiatry* 1986;49: 524-528.
 55. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. *Surg Neurol* 1998;49: 436-440.
 56. Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW, Burger PC, Herndon JE 2nd, Meisler WJ, Schold SC Jr. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. *Ann Neurol* 1991;29: 347-355.
 57. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Stanus E, Brotchi J, Hildebrand J. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. *Cancer* 1996;78: 1098-1106.
 58. Griffeth LK, Rich KM, Dehdashti F, Simpson JR, Fusselman MJ, McGuire AH, Siegel BA. Brain metastases from non-central nervous system tumors: evaluation with PET. *Radiology* 1993;186: 13-15.
 59. Grosu AL, Feldmann H, Dick S, Dzewas B, Nieder C, Gumprecht H, Frank A, Schwaiger M, Molls M, Weber WA. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. *Int J Radiat Oncol Biol Phys* 2002;54: 842-854.

5. Literaturverzeichnis

60. Guth-Tougelidis B, Müller St, Mehdorn MM, Knust EJ, Dutschkla K, Reiners Chr. Uptake of DL-3-123I-iodo-alpha-methyltyrosine in recurrent brain tumors. *Nuklearmedizin* 1995;34: 71-75.
61. Hautzel H, Müller-Gärtner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. *J Nucl Med* 1997;38: 1384-1386.
62. Heiss P, Mayer S, Herz M, Wester HJ, Schweiger M, Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F] fluoroethyl)-L-tyrosine in vitro and in vivo. *J Nucl Med* 1999;40: 1367-1373.
63. Henze M, Mohammed A, Mier W, Rudat V, Dietz A, Nollert J, Eisenhut M, Haberkorn U. Pretreatment evaluation of carcinomas of the hypopharynx and larynx with ¹⁸F-fluorodeoxyglucose, ¹²³I-alpha-methyl-L-tyrosine and ^{99m}Tc-hexakis-2-methoxyisobutylisonitrile. *Eur J Nucl Med Mol Imaging* 2002;29: 324-330.
64. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, Mendoza G, Weber-Luxenburger G, Lottgen J, Thiel A, Wienhard K, Heiss WD. 11C-methionine PET for differential diagnosis of low-grade gliomas. *Neurology* 1998;50: 1316-1322.
65. Herholz K, Pietrzyk U, Voges J, Schroder R, Halber M, Treuer H, Sturm V, Heiss WD. Correlation of glucose consumption and tumor cell density in astrocytomas: a stereotactic PET study. *J Neurosurg* 1993;79: 853-858.
66. Inoue T, Ogasawara K, Beppu T, Ogawa A, Kabasawa H. Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas. *Clin Neurol Neurosurg* 2005;107: 174-180.
67. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, Senda M. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumour tissues be measured in vivo? *J Nucl Med* 1993;34: 1963-1943.
68. Jager PL, Franssen EJ, Kool W, Szabo BG, Hoekstra HJ, Groen HJ, de Vries EG, van Imhoff GW, Vaalburg W, Piers DA. Feasibility of tumor imaging using L-3-[iodine-123]-iodo-alpha-methyl-tyrosine in extracranial tumors. *J Nucl Med* 1998;39:1736-1743.
69. Jager PL, Groen HJ, van der Leest A, van Putten JW, Pieterman RM, de Vries EG, Piers DA. L-3-[123I]iodo-alpha-methyl- Tyrosine SPECT in non-small cell lung cancer: preliminary observations, *J Nucl Med* 2001;42: 579-585.
70. Jager PL, Plaat BE, de Vries EG, Molenaar WM, Vaalburg W, Piers DA, Hoekstra HJ. Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. *Clin Cancer Res* 2000;6: 2252-2259.
71. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. *J Nucl Med* 2001;42: 432-445.
72. Kallen K, Burtscher IM, Holtas S, Ryding E, Rosen I. 201Thallium SPECT and 1H-MRS compared with MRI in chemotherapy monitoring of high-grade malignant astrocytomas. *J Neurooncol* 2000;46: 173-185.
73. Kallen K, Heiling M, Andersson AM, Brun A, Holtas S, Ryding E. Preoperative grading of glioma malignancy with thallium-201 single-photon emission CT: comparison with conventional CT. *AJNR Am J Neuroradiol* 1996;17: 925-932.
74. Kao CH, ChangLai SP, Chieng PU, Yen RF, Yen TC. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-

5. Literaturverzeichnis

- deoxyglucose positron emission tomography and comparison with computed tomography. *J Clin Oncol* 1998;16: 3550-3555.
75. Kaplan WD, Takvorian T, Morris JH, Rumbaugh CL, Connolly BT, Atkins HL. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. *J Nucl Med* 1987;28: 47-52.
 76. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A, Reznik M. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. *J Nucl Med* 1998;39: 778-785.
 77. Khuri FR, Shin DM, Glisson BS, Lippmann SM, Hong WK. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future developments. *Semin Oncol* 2000;27: 25-33.
 78. Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA, Tilbury RS, Yang DJ, Yung WK, Moser RP Jr, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. *Radiographics* 1992;12: 269-279.
 79. Kinuya K, Ohashi M, Itoh S, Yamamoto K, Sakai S, Kakuda K, Nobata K, Kato N, Terahara S, Taki S. Differential diagnosis in patients with ring-like thallium-201 uptake in brain SPECT. *Ann Nucl Med* 2002;16: 417-421.
 80. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. *Brain Pathol* 1993;3: 255-268.
 81. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. *J Neurosurg* 1993; 79: 533-536.
 82. Krummreich C, Holsbach M, Stöcklin G. Direkt electrophilic radioiodination of tyrosine analogues: their in-vivo stability and brain uptake in mice. *Appl Radiat Isot* 1994; 45: 929-935
 83. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. *J Nucl Med* 1992;33: 1972-1980.
 84. Kugel H, Heindel W, Ernestus RI, Bunke J, du Mesnil R, Friedmann G. Human brain tumors: spectral patterns with localized H-1 MR Spectroscopy. *Radiology* 1992;183: 701-709.
 85. Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, Schäffers M, Wassmann H, Schober O. Influence of size of regions of interest on the measurement of uptake of iodine-123- α -methyl tyrosine by brain tumors. *Nucl Med Commun* 1996;17: 609-615.
 86. Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, Matheja P, Brandau W, Wassmann H, Schober O. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. *J Nucl Med* 1998;39: 23-27.
 87. Langen KJ, Cohnen HH, Roosen N, Kling P, Muzik O, Herzog H, Kuwert T, Stöcklin G, Feinendegen LE. SPECT studies of brain tumors with L-3-[123]iodo- α -Methyltyrosine: comparison with PET, 124IMT and first clinical results. *J Nucl Med* 1990;31: 281-286.
 88. Langen K-J, Mühlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH. Transport mechanisms of 3-[123]iodo- α -methyl-L-tyrosine in a human glioma cell line: Comparison with [Methyl-3H]-L-methionine. *J Nucl Med* 2000;41: 1250-1255.

5. Literaturverzeichnis

89. Langen K-J, Pauleit D, Coenen HH. 3-(123I)-Iodo- α -methyl-L-tyrosine: uptake mechanisms and clinical applications. *Nucl Med Biol* 2002;29: 625-631.
90. Langen K-J, Roosen N, Coenen HH, Kuikka JT, Kuwert T, Herzog H, Stöcklin G, Feinendegen LE. Brain and brain tumour uptake of L-3-[123I]iodo- α -methyltyrosine: Competition with natural L-amino acids. *J Nucl Med* 1991;32: 1225-1228.
91. Langen KJ, Ziemons K, Kiwit JCW, Herzog H, Kuwert T, Bock WJ, Stöcklin G, Feinendegen LE, Müller-Gärtner HW. 3-[123I]Iodo- α -Methyltyrosine and [Methyl-11C]-L-Methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. *J Nucl Med* 1997;38: 517-522.
92. Langen, K-J, Clauss RP, Holschbach M, Mühlensiepen H, Kiwit JCW, Zilles K, Coenen HH, Müller-Gärtner H-W. Comparison of iodotyrosines and methionine uptake in a rat glioma model. *J Nucl Med* 1998;39: 1596-1599.
93. Lapela M, Grenman R, Kurki T, Joensuu H, Leskinen S, Lindholm P, Haaparanta M, Ruotsalainen U, Minn H. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. *Radiology* 1995;197: 205-211.
94. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. *Nucl Med Commun* 1996;17: 197-198.
95. Lee SH, Rao KCVG, Zimmermann RA (eds) *Cranial MRI and CT*. McGraw Hill, New York (1992).
96. Leeds NE, Jackson EF. Current imaging techniques for the evaluation of brain neoplasms. *Curr Opin Oncol* 1994;6: 254-261.
97. Lemke AJ, Sander B, Balzer T, Geens V, Hosten N, Felix R. Sicherheit und Nutzen von Gadobutrol bei Patienten mit zerebralen Tumoren (Phase III Studie). *Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr* 1997;167: 591-598.
98. Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Joensuu H. Uptake of C-11-methionine in breast cancer studied by PET: an association with the size of S-phase fraction. *Br J Cancer* 1991;64: 1121-1124.
99. Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M, Joensuu H. Carbon-11-methionine and PET is an effective method to image head and neck cancer. *J Nucl Med* 1992;33: 691-695.
100. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in Non-Hodgkin's Lymphoma: a PET study. *J Nucl Med* 1991;32: 1211-1218.
101. Levivier M, Goldman S, Pirotte B, Brucher JM, Baleriaux D, Luxen A, Hildebrand J, Brotchi J: Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. *J Neurosurg* 1995;82: 445-452.
102. Lichy MP, Henze M, Plathow C, Bachert P, Kauczor HU, Schlemmer HP. Metabolische Bildgebung zur Verlaufskontrolle stereotaktisch bestrahlter Gliome - Wertigkeit der ¹H-MR-Spektroskopie im Vergleich zur FDG-PET und IMT-SPECT. *Fortschr Röntgenstr* 2004;176: 1114-1121.
103. Lilja A, Bergstrom K, Hartvig P, Spannare B, Halldin C, Lundqvist H, Langstrom B. Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography. *AJNR Am J Neuroradiol* 1985;6: 505-514.

5. Literaturverzeichnis

104. Lilja A, Lundqvist H, Olsson Y, Spannare B, Gullberg P, Langstrom B. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. *Acta Radiol* 1989;30: 121-128.
105. Lindholm P, Leskinen S, Nagren K, Lehtikoinen P, Ruotsalainen U, Teras M, Joensuu H. Carbon-11-methionine PET imaging of malignant melanoma. *J Nucl Med* 1995;36: 1806-1810.
106. Lindholm P, Leskinen-Kallio S, Grenman R, Lehtikoinen P, Nagren K, Teras M, Ruotsalainen U, Joensuu H. Evaluation of response to therapy in head and neck cancer by positron emission tomography and 11C-methionine. *Int J Rad Oncol Biol Phys.* 1995;32: 787-794.
107. Liu SH, Chang JT, Ng SH, Chan SC, Yen TC. False positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient. *Br J Radiol* 2004;77: 257-260.
108. Lowe V, Stack B. PET imaging in head and neck cancer. In: Valk P et al. (eds.). *Positron emission tomography - basic science and clinical practice*. London: Springer-Verlag, 2003: 535-546.
109. Ludemann L, Wurm R, Zimmer C. Pharmacokinetic modeling of Gd-DTPA extravasation in brain tumors. *Invest Radiol.* 2002;37: 562-570.
110. Marks JE, Wong J. The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. *Prog Exp Tumor Res* 1985;29: 210-218.
111. Maruyama I, Sadato N, Waki A, Tsuchida T, Yoshida M, Fujibayashi Ishii Y, Kubota T, Yonekura Y. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. *J Nucl Med* 1999;40: 1085-1090.
112. Matheja P, Rickert CH, Weckesser M, Palkovic S, Löttgen J, Riemann B, Kopka K, Kuwert T, Wassmann H, Paulus W, Schober O. Sequential scintigraphic strategy for the differentiation of brain tumours. *Eur J Nucl Med* 2000;27: 550-558.
113. Matheja P, Weckesser M, Rickert Ch, Franzius Ch, Palkovic St, Riemann B, Schober O. I-123-Iodo-alpha-methyl tyrosine SPECT in non-parenchymal brain tumours. *Nuklearmedizin* 2002;41: 191-196.
114. Meyer GJ, Schober O, Hundeshagen H. Uptake of 11C-L- and D-methionine in brain tumors. *Eur J Nucl Med* 1985;10: 373-376.
115. Mineura K, Yasuda T, Kowada M, Ogawa T, Shishido F, Uemura K. Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas. *J Neurooncol* 1987;5: 277-285.
116. Mineura K, Yasuda T, Kowada M, Sakamoto T, Ogawa T, Shishido F, Uemura K. Positron emission tomographic evaluation in the diagnosis and therapy of multifocal glioblastoma Report of a pediatric case. *Ped Neuroscience* 1985;12: 208-212.
117. Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergstrom M, Eriksson L, Johnstrom P. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. *Acta Radiol* 1989;30: 225-232.
118. Myers E, Leffall L. *Head and neck oncology: diagnosis, treatment and rehabilitation*. Boston, Little Brown, 1991

5. Literaturverzeichnis

119. Negendank WG, Sauter R, Brown TR, Brown TR, Evelhoch JL, Falini A, Gotsis ED, Heerschap A, Kamada K, Lee BC, Mengeot MM, Moser E, Padavic-Shaller KA, Sanders JA, Spraggins TA, Stillman AE, Terwey B, Vogl TJ, Wicklow K, Zimmerman RA. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. *J Neurosurg* 1996;84: 449-458.
120. Nelson SJ. Imaging of brain tumors after therapy. *Neuroimaging Clin N Am* 1999;9: 801-819.
121. Nishiyama Y, Yamamoto Y, Fukunaga K, Satoh K, Kunishio K, Ohkawa M. Comparison of ⁹⁹Tc-m-MIBI with ²⁰¹Tl chloride SPET in patients with malignant brain tumours. *Nucl Med Commun* 2001;22: 631-639.
122. Nuutinen J, Jyrkkio S, Lehtikoinen P, Lindholm P, Minn H. Evaluation of early response to radiotherapy in head and neck cancer measured with [¹¹C]methionine-positron emission tomography. *Radiother Oncol* 1999;52: 225-232.
123. Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, Mineura K, Uemura K. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-¹¹C-methionine. *AJNR Am J Neuroradiol* 1996;17: 345-353.
124. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, Shimosegawa E, Ito H, Hatazawa J, Okudera T. Cerebral glioma: evaluation with methionine PET. *Radiology* 1993;186: 45-53.
125. Oriuchi N, Tamura M, Shibasaki T, Ohye C, Watanabe N, Tateno M, Tomiyoshi K, Hirano T, Inoue T, Endo K. Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities. *J Nucl Med* 1993;34: 2085-2089.
126. O'Tuama LA, Treves ST, Larar JN, Packard AB, Kwan AJ, Barnes PD, Scott RM, Black PM, Madsen JR, Goumnerova LC, et al. Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. *J Nucl Med* 1993;34: 1045-1051.
127. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC. Prediction of pathology and survival by FDG PET in gliomas. *J Neurooncol* 2003;64: 227-237.
128. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM. Prediction of survival in glioma patients by means of positron emission tomography. *J Neurosurg* 1985;62: 816-822.
129. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller HW, Zilles K, Coenen HH, Langen KJ. O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. *Brain* 2005;128: 678-687.
130. Pauleit D, Floeth F, Tellmann L, Hamacher H, Hautzel H, Müller HW, Coenen HH, Langen KJ. Comparison of O-(2-¹⁸F-Fluoroethyl)-L-Tyrosine PET and 3-¹²³I-Iodo- α -Methyl-L-Tyrosine SPECT in brain tumors. *J Nucl Med* 2004;45: 374-381.
131. Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Fluss MO, Hamacher K, Coenen HH, Langen KJ. ¹⁸F-FET PET Compared with ¹⁸F-FDG PET and CT in Patients with Head and Neck Cancer. *J Nucl Med* 2006;47: 256-261.

5. Literaturverzeichnis

132. Pigott K, Dische S, Saunders MI. Where exactly does failure occur after radiation in head and neck cancer? *Radiother Oncol* 1995;37: 17-19.
133. Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust R, Stockhammer F, Gutberlet M, Röttgen R, Ruf J, Felix R. Value of ¹²³I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. *Neuroradiology* 2005;47: 18-26.
134. Plotkin M, Eisenacher J, Bruhn H, Wurm R, Michel R, Stockhammer R, Feußner A, Dudeck O, Wust P, Felix R, Amthauer H. ¹²³I-IMT SPECT and ¹H MR-spectroscopy at 3.0 Tesla in the differential diagnosis of recurrent or residual gliomas: a comparative study. *J Neuro Oncol* 2004;70: 49-58.
135. Plotkin M, Gneveckow U, Meier-Hauff K, Amthauer H, Feußner A, Denecke T, Gutberlet M, Jordan A, Felix R, Wust P. ¹⁸F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma *Int J Hyperthermia* 2006 (im Druck).
136. Plotkin M, Hautzel H, Krause BJ, Mohr S, Langen KJ, Müller HW. Fluorine-18-labeled fluorodeoxyglucose-positron emission tomography studies of acute brainstem Lyme neuroborreliosis. Case report. *J Neurosurgery* 2005;102: 927-929.
137. Plotkin M, Stockhammer F, Woiciechowsky Chr, Ruf J, Amthauer H, Felix R. FDG-PET for evaluation of brain tumors showing no or slight Gd-enhancement in the MRI: correlation with intraoperative biopsy. *J Nucl Med* 2005; 46 (suppl 2): 984.
138. Plotkin M, Stockhammer F, Woiciechowsky Chr, Thomale UW, Lehmann TN, Amthauer H, Felix R. Use of F-18 FET-PET for biopsy planning of brain lesions showing no Gd-enhancement in the MRI: first experiences. *Nuklearmedizin* 2006; 45: P83.
139. Plotkin M, Wurm R, Eisenacher J, Szerewicz K, Michel R, Schlenger L, Pech M, Denecke T, Kuczer D, Bischoff A, Felix R, Amthauer H. Combined SPECT/CT Imaging Using ¹²³I-IMT in the detection of recurrent or persistent head and neck cancer. *Eur Radiology* 2006;16:503-511.
140. Plotkin M, Wurm R, Kuczer D, Wust P, Michel R, Denecke T, Ruf J, Schlenger L, Bischoff A, Felix R, Amthauer H. Diagnostic Value of ¹²³I-IMT SPECT in the Follow-up of Head and Neck Cancer. *Onkologie* 2006; 29:147-152.
141. Popperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspotter M, Tonn JC, Tatsch K. O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. *Eur J Nucl Med Mol Imaging* 2005;32: 1018-1025.
142. Popperl G, Gotz G, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. *Eur J Nucl Med Mol Imaging* 2004;11: 1464-1470.
143. Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, Pokrupa R, Arnold DL. Accurate, non-invasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. *Nat Med* 1996;2: 323-325.
144. Rabinov JD, Lee PL, Barker FG, Louis DN, Harsh IV GR, Rees Cosgrove GR, Chiokka EA, Thornton AF, Loeffel JS, Henson JW Gonzalez RG. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. *Radiology* 2002;225: 871-879.

5. Literaturverzeichnis

145. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. *J Nucl Med* 1997;38: 280-287.
146. Ricci M, Pantano P, Pierallini A, Di Stefano D, Santoro A, Bozzao L, Lenzi GL. Relationship between thallium-201 uptake by supratentorial glioblastomas and their morphological characteristics on magnetic resonance imaging. *Eur J Nucl Med* 1996;23: 524-529.
147. Ricci PE, Karis JP, Heisermann JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? *AJNR* 1998;19: 407-413.
148. Riemann B, Könemann S, Pöppling D, Kopka K, Weckesser M, Willig N, Schober O. Early effects of irradiation on [123I]-IMT and [18F]-FDG uptake in rat C6 glioma cells, *Strahlenther Onkol* 2004;180: 434-441.
149. Riemann B, Papke K, Hoess N, Kuwert T, Weckesser M, Matheja P, Wassmann H, Heindel W, Schober O. Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT. *Radiology* 2002;225: 567-574.
150. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. *Radiology* 2003;226: 181-187.
151. Rollins NK, Lowry PA, Shapiro KN. Comparison of gadolinium-enhanced MR and thallium-201 single photon emission computed tomography in pediatric brain tumors. *Pediatr Neurosurg* 1995;22: 8-14.
152. Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BF, Feiden W, Kirsch CM. Clinical value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis or recurrent brain tumor in patients pretreated for glioma at follow-up. *J Clin Oncol* 2002;15: 396-404.
153. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, Morioka T, Fukui M, Masuda K. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. *Eur J Nucl Med* 1998;25: 1261-1269.
154. Sato K, Baba Y, Inoue M, Omori R. Radiation necrosis and brain edema association with cyberKnife treatment. *Acta Neurochir Suppl* 2003;86: 513-517.
155. Sato N, Suzuki M, Kuwata N, Kuroda K, Wada T, Beppu T, Sera K, Sasaki T, Ogawa A: Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. *Neurosurg Rev* 1999;22: 210-214.
156. Schedel H, Felix R. [Magnetic resonance tomographic characterization of intracranial tumors by evaluating the blood-brain barrier and regional cerebral circulation]. *Aktuelle Radiol.* 1993;3: 346-350.
157. Schlegel U, Westphal M. (Hrsg.) *Neuroonkologie*. Georg Thieme, Stuttgart, New York. (1998).
158. Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, Kaick G. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. *Am J Neuroradiol* 2001;22: 1316-1324.

5. Literaturverzeichnis

159. Schmidt D, Gottwald U, Langen KJ, Weber F, Hertel A, Floeth F, Felsberg J, Reifenberger G, Coenen HH, Muller-Gartner HW. 3-[123I]Iodo- α -methyl-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. *Eur J Nucl Med* 2001;28: 855-861.
160. Schmidt D, Wunderlich G, Langen K-J et al. I-123- α -Methyl-Tyrosine (IMT) SPECT for evaluation of chemotherapy in cerebral gliomas. *J Nucl Med* 1996;37: 354P.
161. Schmidt M, Schmalenbach M, Jungehülsing M, Thiessen P, Dietlein M, Schröder U, Eschner W, Stennert E, Schicha H: ^{18}F -FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis. *Nuklearmedizin* 2004;43: 91-101.
162. Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. *Radiology* 1996;201: 275-278.
163. Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, Probst A, Gratzl O, Reubi JC, Maecke R, Mueller-Brand J, Merlo A. Local injection of the ^{90}Y -labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. *Eur J Nucl Med Mol Imaging* 2002;29: 486-493.
164. Schwartz LH, Ozsahin M, Zhang GN, Touboul E, De Vataire F, Andolenko P, Lacau-Saint-Guilly J, Laugier A, Schlienger M. Synchronous and metachronous head and neck carcinomas. *Cancer* 1994;74: 1933-1938.
165. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. *RadioGraphics* 1999;19: 61-77.
166. Soler C, Beauchesne P, Maatougui K, Schmitt T, Barral FG, Michel D, Dubois F, Brunon J. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. *Eur J Nucl Med*. 1998;25:1649-1657.
167. Som PM. Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. *Am J Roentgenol* 1992;158: 961-969.
168. Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T. Clinical usefulness of ^{11}C -MET PET and ^{201}Tl SPECT for differentiation of recurrent glioma from radiation necrosis. *Neurol Med Chir (Tokyo)*. 1998;38: 342-347.
169. Spence AM, Muzi M, Graham MM, O'Sullivan F, Link JM, Lewellen TK, Lewellen B, Freeman SD, Mankoff DA, Eary JF, Krohn KA. 2-[^{18}F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. *Clin Cancer Res* 2002;8: 971-979.
170. Stadlbauer A., Moser E, Gruber S, Nimsky Chr, Fahlbusch R, Ganslandt O. Integration of biochemical images of a tumor into frameless stereotaxy achieved using a magnetic resonance imaging/magnetic resonance spectroscopy hybrid data set. *J Neurosurg* 2004;101: 287-294.
171. Staffen W, Hondl N, Trinkla E, Iglseder B, Unterrainer J, Ladurner G. Clinical relevance of ^{201}Tl -chloride SPET in the differential diagnosis of brain tumours. *Nucl Med Commun* 1998;19: 335-340.
172. Sun D, Liu Q, Liu W, Hu W. Clinical application of ^{201}Tl SPECT imaging of brain tumors. *J Nucl Med* 2000;41: 5-10.

5. Literaturverzeichnis

173. Tang G, Wang M, Tang X, Luo L, Gan M. Pharmkokinetics and radiation ndosimetry estimation of O-(2-[18F] floreoethyl)-L-tyrosine as oncologic PET tracer. *Appl Radiat Isot* 2003;58: 219-225.
174. Taylor JS, Langston JW, Reddick WE, Kingsley PB, Ogg RJ, Pui MH, Kun LE, Jenkins JJ 3rd, Chen G, Ochs JJ, Sanford RA, Heideman RL. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. *Int J Radiat Oncol Biol Phys* 1996;36: 1251-1261.
175. Tovi M, Lilja A, Bergstrom M, Ericsson A, Bergstrom K, Hartman M. Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. *Acta Radiol* 1990;31: 417-429.
176. Träber F, Block W, Flacke S, Lamerich R, Schüller H, Urbach H, Keller E, Schild HH: 1H-MR Spectroscopy of brain tumors in the course of radiation therapy: use of fast spectroscopic imaging and single-voxel spectroscopy for diagnosing recurrence. *Fortschr Röntgenstr* 2002;174: 33-42.
177. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, Otsuka Y, Sakamoto S, Ohata K, Goto T, Hara M. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? *J Neurosurg* 2003;98: 1056-1064.
178. Utraiainen M, Komu M, Vuorinen V, Lehikoinen P, Sonninen P, Kurki T, Utraiainen T, Roivainen A, Kalimo H, Minn H. Evaluation of brain tumor metabolism with [11C] choline PET and 1H-MRS. *J Neurooncol* 2003;62: 329-338.
179. Van Tassel P, Leeds NE. Diagnostic imaging advances in neurooncology. *Curr Opin Oncol* 1991;3: 439-448.
180. Voges J, Herholz K, Holzer T, Wurker M, Bauer B, Pietrzyk U, Treuer H, Schroder R, Sturm V, Heiss WD. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. *Stereotact Funct Neurosurg* 1997;69: 129-135.
181. Vogl TJ, Friebe CE, Balzer T, Mack MG, Steiner S, Schedel H, Pegios W, Lanksch W, Banzer D, Felix R. Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study. *Radiologe* 1995;35: 508-516.
182. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. *N Engl J Med* 1993;328: 184-194.
183. Warburg O. On the origin of cancer cells. *Sciences* 1956;123: 309-314.
184. Weber W, Bartenstein P, Gross MW, Kinzel D, Daschner H, Feldmann HJ, Reidel G, Ziegler SI, Lumenta C, Molls M, Schwaiger M. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. *J Nucl Med* 1997;38: 802-808.
185. Weber W, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stocklin G, Schwaiger M. O-(2-[18F] fluoroethyl)-L-tyrosine and L-[methyl-11C] methionine uptake in brain tumours: initial results of a comparative study. *Eur J Nucl Med* 2000;27: 542-549.
186. Weber WA, Dick S, Reidl G, Dzewas B, Busch R, Feldmann HJ, Molls M, Lumenta CB, Schwaiger M, Grosu AL. Correlation between postoperative 3-[(123)I]iodo-L-alpha-

5. Literaturverzeichnis

- methyltyrosine uptake and survival in patients with gliomas. *J Nucl Med* 2001;42: 1144-1150.
187. Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K, Kurlemann G, Wassmann H, Coenen HH, Schober O. O-(2-[18F]fluoroethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. *Eur J Nucl Med Mol Imaging* 2005; 32: 422-429.
188. Weckesser M, Matheja P, Rickert CH, Strater R, Palkovic S, Lottgen J, Kurlemann G, Paulus W, Wassmann H, Schober O. High uptake of L-3-[123I]iodo-alpha-methyl tyrosine in pilocytic astrocytomas. *Eur J Nucl Med* 2001;28: 273-281.
189. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stocklin G. Synthesis and radiopharmacology of O-(2-[18F] fluoroethyl)-L-tyrosine for tumor imaging. *J Nucl Med* 1999;40: 205-212.
190. Wieder H, Ott K, Zimmermann F, Nekarda H, Stofffuss J, Watzlowik P, Siewert JR, Fink U, Becker K, Schwaiger M, Weber WA. PET imaging with [(11)C]methyl-L-methionine for therapy monitoring in patients with rectal cancer. *Eur J Nucl Med Mol Imaging* 2002;29: 789-796.
191. Wienhard K, Herholz K, Coenen HH, Rudolf J, Kling P, Stöcklin G, Heiss WD. Increased amino acid transport into brain tumors measured by PET of L-[2-18F]fluoro-tyrosine. *J Nucl Med* 1991;32: 1338-1346.
192. Wilken B, Dechent P, Herms J, Maxton C, Markakis E, Hanefeld F, Frahm J: Quantitative proton magnetic resonance spectroscopy of focal brain lesions. *Ped Neurol* 2000;23: 22-31.
193. Willkomm P, Bangard M, Guhlke S; Sartor J, Bender H, Gallkowski U, Reichmann K, Biersack HJ. Comparison of [18F]FDG-PET and L-3[123I]-iodo-alpha-methyl tyrosine (I-123 IMT)-SPECT in primary lung cancer. *Ann Nucl Med* 2002;16: 503-506.
194. Woesler B, Kuwert T, Morgenroth C, Matheja P, Palkovic S, Schafers M, Vollet B, Schafers K, Lerch H, Brandau W, Samnick S, Wassmann H, Schober O. Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123- Iodo- α -methyl tyrosine and PET with 18F-deoxyglucose. *Eur J Nucl Med* 1997;24: 428-434.
195. Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, Pfister DG, Shah JP, Larson SM, Kraus DH: Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. *J Clin Oncol* 2002;20:4199-4208.
196. Wowra B, Schmitt HP, Sturm V. Incidence of late radiation necrosis with transient mass effect after interstitial low dose radiotherapy for cerebral gliomas. *Acta Neurochir (Wien)* 1989;99: 104-108.
197. Yamada S, Kubota K, Kubota R, Ido T, Tamashashi N: High accumulation of fluorine-fluorodeoxyglucose in terpine-induced inflammatory tissue. *J Nucl Med* 1995;36: 1301-1306.
198. Yokogami K, Kawano H, Moriyama T, Uehara H, Sameshima T, Oku T, Goya T, Wakisaka S, Nagamachi S, Jinnouchi S, Tamura S. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET? *Eur J Nucl Med*. 1998;25: 401-509.